Rafael Fonseca/X
Sep 3, 2025, 10:08
Rafael Fonseca: Classifying Myeloma Treatments as Curative Versus Control Ones
Rafael Fonseca, Chief Innovation Officer and Professor of Medicine at Mayo Clinic, shared a post on X:
“Classifying myeloma treatments as curative versus control ones – the time is now!”
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared this post, adding:
“Brilliant summary of Bruno Paiva research into MRD myeloma. (Although I’d wager that MRD-neg ≥VGPR at an early timepoint as MRD-neg CR).
Eloquently worded by Rafael Fonseca: I’m excited for the day that CR vs VGPR vs PR is relegated to a legacy academic exercise alone!”
More posts featuring Rafael Fonseca and Rahul Banerjee.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 3, 2025, 09:59
Sep 3, 2025, 09:57
Sep 3, 2025, 09:53
Sep 3, 2025, 09:50
Sep 3, 2025, 09:39